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Abstract 
Ovarian cancer survivors may experience Quality of Life (QOL) disruptions due to the 
aggressiveness of the illness and its treatment. The present manuscript intends to review the most 
recent knowledge regarding QOL in ovarian cancer survivors. Firstly, a brief overview about 
QOL, their importance and instruments used to assess it particularly in ovarian cancer survivors 
are presented. Then, main findings and developments achieved to date are discussed. Main 
conclusions from studies reviewed and future research needs are outlined. Available literature 
suggests that in general ovarian cancer survivors experience a good QOL; however, some deficits 
are more prevalent than in women without cancer. Although, these studies brought to light 
important QOL issues, more rigorous and larger studies are necessary to fully understand ovarian 
cancer survivors' QOL. Measuring QOL in ovarian cancer survivors in clinical settings is of 
utmost importance to identify those survivors at risk and provide adequate support that meets their 
needs.  
Keywords: Quality of Life, Ovarian cancer survivors.  
 
Introduction 
Ovarian cancer is the most fatal malignancy of the female genital tract and the fourth 
most common cause of female cancer death (Siegel, Naishadham and Jemal, 2012). It is 
an aggressive illness associated with very poor survival and high recurrence rates. 
Generally, ovarian cancer is detected at an advance stage, with a 5-year survival rate of 
46 % for all the stages and 31 % for advanced stages (Siegel et al., 2012). The 
management of ovarian cancer normally includes radical pelvic surgery and multiple 
aggressive courses of chemotherapy. Women may suffer debilitating disease-related 
symptoms, such as weight loss, bloating and ascites, fatigue and pain and a wide range of 
treatment sequelae (Gonçalves, 2010; Stavraka et al., 2012).  Examples of treatment 
related sequelae include neutropenia, body distortion, hair loss, bowel and bladder 
incontinence, loss of taste and appetite, premature menopause, infertility, decrease 
physical functioning, poor sleep, edema and sexual problems (Gonçalves, 2010; Stavraka 
et al., 2012). 
The stress of receiving the diagnosis of such an aggressive and life threatening illness, 
may be associated with uncertainty and anxiety about the future. In fact, ovarian cancer 
may be perceived as a traumatic event and may have a strong psychological impact on 
the survivor and her Quality of Life (QOL) (Gonçalves, Jayson and Tarrier, 2008, 2011). 
Following this line, research carried out, specifically, with ovarian cancer patients has 
shown that a substantial proportion of women experience psychological disorders. 
Anxiety, depression and Post Traumatic Stress Disorder (PTSD) have been reported 
(Gonçalves et al., 2008; Huang, Cronin and Johnson, 2008; Gonçalves et al., 2011; Hess 
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and Stehman, 2012). Qualitative studies and Quality of Life studies have shown that 
significant distress, impairments in physical, vocational, social, familial and sexual 
functioning may also occur (WHOQOL, 1993; Bowling 2001; Ferrell et al., 2003; 
Norton et al., 2004; Gonçalves et al., 2011; Chase and Wenzel, 2011). In this context, we 
conducted a prospective longitudinal study to measure psychological disorders, such as 
anxiety and depression, perceived social support, neuroticism and coping strategies to 
control unwanted thoughts in ovarian cancer patients (Gonçalves et al., 2008). These 
were measured at similar time points; which were the beginning of chemotherapy 
treatment, mid-treatment, end of treatment and 3 months follow-up post-treatment, The 
results showed that there were three patterns of anxiety and depression over time: 
absence of caseness (never a case), occasional or intermittent cases and persistent cases 
(cases at all the time points). The majority of the women were cases of anxiety at some 
occasions (52 %), while 38 % were cases of depression at some time points. Also, a 
subset of women were persistent cases of anxiety (22 %) and a smaller number suffered 
persistent depression (6 %) (Gonçalves et al., 2008). 
Although ovarian cancer patients do not belong to the largest cancer survivor population, 
there is a subset of women, who live years after the diagnosis without symptoms of the 
disease. Although, most of these survivors return to their normal functioning, they often 
need to deal with physical and psychological sequelae that persist for a long-term period 
and have a negative impact on their QOL. The understanding that the study of QOL 
outcomes in ovarian cancer survivors is of utmost importance, led to the emergence of a 
body of research that has been targeting QOL issues in ovarian cancer. The knowledge 
about these issues is crucial to provide appropriate clinical support that meets survivors' 
needs, and ultimately, improve their QOL. The present manuscript addresses the most 
recent knowledge regarding QOL in ovarian cancer survivors. Firstly, a brief overview 
about QOL, their importance and instruments used to assess it particularly in ovarian 
cancer survivors are presented. Then, main findings and developments achieved to date 
are discussed. Main conclusions from studies reviewed and future research needs are 
outlined. 
 
Quality of Life: an overview 
Although the definition of QOL is not consensual, it is generally accepted that it is a 
multidimensional construct that encompasses several important dimensions (any area of 
behavior or experience) (Cella et al., 1993; Ferrell et al., 2003; Gonçalves et al., 2008; 
Hess and Stehman, 2012). These include physical functioning (physical well-being, 
mobility, ability to perform self-care activities, physical activities, role activities such as 
work or housework, appetite, comorbidities, fatigue/sleep, symptoms, side-effects), 
cognitive and psychological functioning (emotional well-being, anxiety, depression, 
coping, perceptions, prior experience, enjoyment, optimism), social functioning (family 
interactions, time with friends, leisure activities), disease and treatment related symptoms 
(such as pain and fatigue), spiritual or existential concerns, sexual functioning, body 
image, patient's satisfaction with health care, control of the disease (Ferrell et al., 2003; 
Hess and Stehman, 2012).  According to the WHO (WHOQOL, 1993), QOL is defined 
as 'an individual's perception of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, standards 
and concerns. It is a broad ranging concept affected in a complex way by the person's 
physical health, psychological state, level of independence, social relationships, and their 
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relationships to salient features of their environment". Therefore, QOL includes all 
aspects of the individual well-being and must be evaluated from the individual's 
perspective.  
The study of QOL outcomes is very relevant in the context of health care provision. 
Primarily, QOL measurement provides information essential to guide clinical decision 
making (Higginson, 2001). The knowledge about the impact of the illness and its 
treatment on cancer patients can help clinicians and patients to make decisions regarding 
treatment options and choose appropriate supportive therapy adjusted to the patient's 
needs (Penson, Wenzel, Vergote and Cella, 2006). Furthermore, QOL data can foster 
patient-clinician interactions in routine practice, identify problems that have a significant 
impact on QOL, prioritize problems, develop interventions to deal with these problems 
and evaluate the impact of palliative and rehabilitative efforts (Jacobsen, Davis and 
Cella, 2002). In addition, it can help to shape public policy and health care decisions 
made by governmental and private institutions (Murphy, Ridner, Wells and Dietrich, 
2007) and allow the economic evaluation of healthcare provision (Velikova, Stark and 
Selby, 1999).   
In general, QOL assessment in ovarian cancer patients has been focusing more on the 
acute phase of the treatment. Researchers have been interested in the evaluation of QOL 
under treatment conditions in randomized clinical trials, focusing on different treatment 
options. The measurement of QOL in screening and early diagnosis of ovarian cancer is 
very scarce. In fact, screening and early detection of ovarian cancer are very limited in 
clinical practice, existing narrow useful technologies to assist in early diagnosis. 
Regarding survivorship, recently, there is a growing interest in the study of QOL in 
ovarian cancer survivors; however, there are still few studies about QOL in this phase of 
the cancer trajectory.  
Different instrument's measures have been developed to evaluate QOL in oncology 
settings. The most commonly used measures to assess QOL in ovarian cancer survivors 
are EORTC QOL-C30 and EORTC QOL-OV28, which may be supplemented by several 
other questionnaires to assess specific dimensions of QOL. The EORTC QOL-C30 is a 
cancer-specific questionnaire developed by the Study Group on Quality of Life from the 
European Organization for Research on Treatment of Cancer comprising a core set of 
questions applicable to all cancer patients and modules to be used to specific cancer 
sides, such as ovarian cancer (Aaronson et al., 1993; Cull et al., 2001).  This instrument 
was designed to be used in international randomized clinical trials. It is based on a 
multidimensional model of QOL, covering cancer-specific symptoms of the disease, 
psychological distress, treatment side-effects, social interaction, physical functioning, 
body image, sexuality, global health and quality of life, and satisfaction with medical 
care. The core QOL instrument is composed by 30 items, comprising nine scales of 
QOL: one global QOL scale (2 items), five functional scales (physical functioning, role 
functioning, cognitive functioning, emotional functioning, social functioning) (15 items), 
three symptom scales (fatigue, pain, nausea and vomiting) (7 items), and six single items, 
assessing additional symptoms commonly reported by cancer patients (breathlessness, 
difficulty sleeping, appetite loss, constipation, diarrhea, and financial difficulties physical 
condition. The EORTC QOL-C30 has established reliability and validity (Aaronson et 
al., 1993). This scale is easy to complete, acceptable to patients and has been translated 
into several languages. The EORTC QOL-OV28 is the ovarian cancer module designed 
to supplement the EORTC QOL-C30, for the assessment of QOL in ovarian cancer 
patients in clinical trials and related studies. It consists of 7 subscales and a total of 28 
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items, which assess abdominal symptoms (abdominal pain, feeling bloated, clothes too 
tight, changed bowel habit, flatulence, fullness when eating, indigestion), peripheral 
neuropathy (tingling, numbness, and weakness), other chemotherapy related side effects 
(hair loss and upset by hair loss, taste change, muscle pain, hearing problem, urinary 
frequency, and skin problem), hormonal/menopausal symptoms (hot flushes and night 
sweat), body image (less attractive, dissatisfied with body), attitude to disease and 
treatment (disease burden, treatment burden, and worry about future) and sexual 
functioning (interest in sex, sexual activity, enjoyment of sex and dry vagina) (Cull et al., 
2001; Greimel et al., 2003). The EORTC QOL-OV28 is a valid and reliable measure to 
be used in ovarian cancer populations (Greimel et al., 2003). These instruments have 
been developed primarily from research environments; however, they are extremely 
helpful if they assist physicians in detecting clinically significant differences or changes 
in a patient condition. 
 
Quality of Life in Ovarian Cancer Survivors 
Collectively, available literature suggests that ovarian cancer survivors have generally 
good QOL; however, specific deficits are more prevalent in ovarian cancer survivors that 
in women without a history of cancer (Steward et al., 2001; Wenzel et al., 2002; 
Matulonis et al., 2008; Mirabeau-Beale et al., 2009; Greimel et al., 2011; Teng, Kalloger; 
Brotto and McAlpine, 2014). An exception is made by a study conducted by Liavaag, 
Dørum, Fosså, Tropé and Dahl (2007) that found that ovarian cancer survivors were 
experiencing poorer QOL than healthy controls. Results concerning psychological 
functioning are inconsistent, ranging from good emotional status to psychological 
distress, including PTSD and depression (Liavaag et al., 2007). Findings from studies 
examining QOL in ovarian cancer survivors are described below. 
One of the first studies addressing QOL in ovarian cancer survivors was conducted by 
Steward, Wong, Duff, Melancon and Cheung (2001) on 200 ovarian cancer survivors, 
who were disease-free at the time of the study. They were assessed on physical, 
psychological and social well-being. Results showed that most of the survivors (89 %) 
regarded their health as good or excellent. A better mental health and equivalent energy 
levels comparing to the general population were found. However, the majority of the 
women experienced pelvic pain and discomfort (54 %). Although 57 % of the survivors 
referred that their sexual life had been negatively affected by the cancer and its treatment, 
their general sense of loss regarding sexual functioning was perceived as moderate to 
low. Women under 55 years of age reported a greater sense of loss about sexual 
functioning and fertility. The experience of surviving ovarian cancer appeared to have 
enriched these women, altering their life priorities and developing on them an impressive 
resilience (Stewart et al., 2001). Furthermore, authors highlighted that these survivors 
showed in general a great pleasure in life and relationships (Stewart et al., 2001). 
Similarly, Wenzel and colleagues (2002), who examined 49 early stage ovarian cancer 
survivors (> 5 years), reported that survivors enjoyed a good QOL, with physical, 
emotional and social well-being comparable same aged samples without a history of 
cancer. Few difficulties were reported, such as problems related to abdominal and 
gynaecological symptoms, and neurotoxicity. In the emotional domain, scores were more 
variable, with only one third of the survivors experiencing an excellent emotional well-
being. Fears of future diagnostic tests (30 %) and recurrence (20 %) were also found. 
Investigators emphasised the resilience and growth that survivors reported in their study 
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as a result of their ovarian cancer experience (Wenzel et al., 2002). Another study 
corroborated the view that ovarian cancer survivors experience a good QOL (Matulonis 
et al., 2008). Respondents experienced good physical QOL, few long-term physical 
symptoms (such as abdominal complaints and neurotoxicity) and few unmet needs. 
However, survivors reported emotional problems, such as psychological distress (40 %), 
anxiety about Ca125 testing (54 %), fear of recurrence (56 %) and 26 % had scores 
suggestive of PTSD. Better mental health was associated with less fatigue and pain, 
fewer stressful life events and higher social support. Sexual problems, namely pain 
during sexual intercourse (52 %) were also reported. Less than 10 % of participants were 
interested in sex or were sexually active (Matulonis et al., 2008). Similarly to previous 
findings, Mirabeau-Beale and colleagues (2009), who conducted the first comparison 
between early stage (58 women) and advanced stage (42 women) survivors on QOL (> 3 
years), physical, sexual and mental function, found that survivors experienced positive 
overall QOL and long-term adjustment. There were no differences between early stage 
and advanced stage survivors on overall QOL, unmet needs, social support, 
complementary therapy use, physical symptoms (neurotoxicity, fatigue and 
comorbidities), functioning (cognitive, sexual, physical, role, emotional and sexuality), 
spirituality, hopelessness and psychological state. However, advanced stage survivors 
experienced better social functioning. Although, the majority of survivors had a good 
emotional functioning, scores suggestive of PTSD were noted in 7 % of early stage 
survivors. Diagnosable PTSD scores were not found in the advance stage survivors 
group. Decreased sexual interest attributed to cancer, physical comorbidities, such as 
degenerative joint disease, gastrointestinal distress and thyroid disease, fear of 
recurrence, use of complementary and alternative medicines (exercise, vitamins, prayer 
and massage) in order to improve their QOL were reported by survivors (Mirabeau-Beale 
et al., 2009). A recent study conducted by Greimel and colleagues examined survivors at 
three time points: pre-treatment (baseline), 1-year after diagnosis and 10 years post-
treatment. At the baseline, 33 survivors were included; of those, 22 died within 5 years 
post diagnosis and 11 survived beyond 10 years. In general, results corroborated previous 
findings reporting that survivors experienced a good physical, psychological, social and 
spiritual health. Despite no differences at baseline in FIGO stage, residual tumor, 
performance status and treatment characteristics between short-term and long-term 
survivors, the latter group experienced better physical functioning, role functioning, 
cognitive functioning and less symptoms than short-term survivors. One year after 
treatment, the majority of the QOL dimensions were comparable among the two groups; 
however, long-term survivors reported better global QOL but more insomnia. Emotional 
functioning and global QOL improved significantly from baseline to 1 year after 
diagnosis and remained relatively stable in the 10 year follow-up evaluation. Long-term 
survivors did not experience more sleeping problems 10 years after their diagnosis than 
women from a general population (Greimel et al., 2011).  Although the majority of 
studies have been reporting that ovarian cancer survivors experience good QOL, Liavaag 
and colleagues  study's contradicted this trend. Authors found that 189 ovarian cancer 
survivors (> 18 months after primary treatment) experienced poorer QOL, had more 
chronic fatigue and mental morbidity, and used more medication and health services 
when compared to age-adjusted controls from the general population.  
Quality of Life's needs of ovarian cancer survivors were investigated in a very recent 
pilot study conducted by Teng and colleagues (2014). A total of 102 ovarian cancer 
survivors completed the EORTC QOL-C30 and the EORTC QOL-OV28 questionnaires. 
Results shown that clinical factors, such as age, stage of the disease, histology did not 
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have a significant impact of survivors' QOL. Task completion, memory, concentration, 
anxiety and fatigue were the distress categories that were given the highest scores by 
survivors. Authors concluded that psychological factors have a larger impact on global 
QOL than physical symptoms. 
 
Conclusion 
Collectively, studies examining QOL outcomes in ovarian cancer survivors reported that 
survivors are generally able to enjoy a QOL, equivalent to their healthy controls; 
however, some deficits are more prevalent in ovarian cancer survivors than in women 
without a history of cancer. Beyond the expected physical and sexual sequelae of the 
illness and treatment, studies highlighted psychological difficulties faced by survivors, 
which may adversely affect their psychological adjustment and well-being. 
Findings from survivorship research are of utmost importance to provide critical 
information to guide the development and design of interventions to assist survivors at 
risk. The care provided to the cancer patient does not cease when the treatment ends. 
Survivorship is now recognized as a phase in the cancer trajectory that requires special 
attention and ongoing specialized care. Over the years, there was a noticeable attempt to 
improve the methodological quality of studies, for example, by using more standardized 
and validate measures to assess QOL in this cancer population. However, small sample 
sizes, heterogeneity of samples, timing of assessments are among the difficulties posed 
by current research, which make problematic to reach definite conclusions. 
Existing studies brought to light, important QOL needs of ovarian cancer survivors; 
however, further larger and rigorous studies are necessary to fully understand QOL in 
ovarian cancer survivors. Among others, these include the use of standardized measures 
and reporting of QOL data from ovarian cancer survivors and common data collection 
time points. These would allow comparative effectiveness research to be carried out 
(Hess and Stehman, 2012). 
In order to fully take advantage of all the benefits offered by QOL research, it is 
imperative that QOL research provides health care professionals with clinically relevant 
and interpretable information that can guide treatment decisions. Furthermore, it is very 
important to routinely assess QOL disruptions in ovarian cancer survivors in order to 
screen and identify patients at risk. Therefore, efforts should target the development of 
interventions to be used in women at need, to prevent or ameliorate the negative impact 
of the illness and its treatment on QOL. The assessment of QOL in clinical settings 
allows the identification of QOL needs throughout the cancer trajectory, which includes 
survivorship. 
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